Biotech Receives FDA Approval of Second-Generation Medical Device

Research Report
  ()
The product's improvements and the company's commercialization approach were summarized in a Ladenburg Thalmann report. read more >
News Update

Healthcare Tech Firm Expands Medical Client Base in Texas

News Update
  ()
These new customers' patient accounts are already being imported into the company's platform. read more >

Interim Results Put Biopharma with Tenbagger Potential 'Back on the Map'

Research Report
  ()
A key upcoming catalyst and the impact of recent positive trial results are addressed in a ROTH Capital Partners report. read more >
News Update

Biotech to Present Alzheimer's Disease Therapeutic at Keystone Symposium

News Update
  ()
The focus will be the Canadian company's lead monoclonal antibody candidate. read more >

Biopharma Receives FDA Fast Track Designation for Cancer Therapeutic

Research Report
  ()
An explanation of the categorization and its implications are provided in a Paradigm Capital report. read more >

Coverage Initiated on Biotech Whose Therapies 'Can Compete with CAR-Ts'

Research Report
  ()
The reasons for the Buy rating on the U.K. firm are delineated in a ROTH Capital Partners report. read more >

Bacteria Test Developer Reiterates Revenue Should Double in 2019

Research Report
  ()
The product expected to drive that outcome is discussed in an H.C. Wainwright & Co. report. read more >
News Update

Healthcare Firm Partners on Genetic Testing for Cannabis, Medication Responses

News Update
  ()
The offering should facilitate a more individualized treatment plan for patients. read more >
News Update

Biotech Identifies Antibodies for Toxic Tau in Alzheimer's Disease

News Update
  ()
The Canadian company's approach to this indication is now twofold. read more >

Biopharma's LDL Cholesterol-Lowering Drug Emerges as 'Lead Stallion in Safety'

Research Report
  ()
The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report. read more >

Expert Investing Ideas

"DRRX's current valuation is an interesting buying opportunity."

–Francois Brisebois, Laidlaw & Company


"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"DRRX's Posimir comes back in play."

–Ed Arce, H.C. Wainwright & Co.


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical

California-Based Biopharma Signs Licensing Deal for Acquired Asset

Research Report
  ()
The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report. read more >

U.S. Biopharma's 'Biggest Stock Moving Event' Imminent

Research Report
  ()
With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report. read more >

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

Research Report
  ()
The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. read more >

Immuno-oncology Firm to Co-Develop Companion Diagnostic for Cervical Dysplasia

Research Report
  ()
The partnership news and upcoming data readouts are reviewed in an H.C. Wainwright & Co. report. read more >